Nyxoah S.A.
NYXH
$-0.12
Change (1 day)
$20.00
Year High
$4.00
Year Low
Categories
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
P/E ratio for Nyxoah S.A. (NYXH)
P/E ratio as of 2023: -2.72
According to Nyxoah S.A.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -2.72. At the end of 2022 the company had a P/E ratio of -3.85.
P/E ratio history for Nyxoah S.A. from 2017 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -2.72 |
| 2022 | -3.85 |
| 2021 | -17.42 |
| 2020 | -29.02 |
| 2019 | -63.20 |
| 2018 | -48.16 |
| 2017 | -40.28 |